The downregulation of TRIM21/Ro52 is associated with a poor prognosis in patients with certain kinds of cancer, including DLBCL, breast cancer, gastric cancer, renal cell carcinoma, ovarian cancer, and colitis-associated cancer [12–14, 40–43] (Table 1). This evidence concerns the gene TRIM21 and hereditary clear cell renal cell carcinoma.